CN1066979A - The preparation method of antibiotics for burn wound - Google Patents
The preparation method of antibiotics for burn wound Download PDFInfo
- Publication number
- CN1066979A CN1066979A CN 91103111 CN91103111A CN1066979A CN 1066979 A CN1066979 A CN 1066979A CN 91103111 CN91103111 CN 91103111 CN 91103111 A CN91103111 A CN 91103111A CN 1066979 A CN1066979 A CN 1066979A
- Authority
- CN
- China
- Prior art keywords
- pon
- preparation
- burn wound
- burn
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A kind of antibiotics for burn wound PON-I is to adopt the iodine Ointment that contains that new drug carrier and substrate makes, and is strong to II degree, III degree burn wound antibacterial action, can guarantee the breathability and the water penetration of wound surface, can shorten the course of disease, improves the cure rate of burn patient.
Description
The present invention relates to a kind of antibiotics for burn wound PON-T(hereinafter to be referred as PON-T) preparation method.
In existing similar technology, the PVP-I of Skelanski development is abroad arranged, commodity Betadine ointment by name and Emulsion, burns unit circle both domestic and external adopts this preparation more, (J.Hyg.62: 509,1964).But slow as bactericidal action up to at present to PVP-I ointment and the long-standing problem of Emulsion, after the large-area burns wound surface coating PVP-I, local water penetration and breathability are bad, influence healing speed, and be greasy, and easy-clear etc. is not all properly settled.
The purpose that the present invention proposes burns unit antibiotic preparation PON-T is for overcoming the existing the problems referred to above of prior art.Through the burns unit clinical verification, stronger antibacterial ability is arranged, and can keep local good water penetration and breathability, thereby for shortening the course of disease, the cure rate that improves burn patient provides advantage.
The objective of the invention is to realize by following technical scheme.
One, one of distinctive points of the technical characterictic of PON-I of the present invention and prior art PVP-I is:
(1) adopts new pharmaceutical carrier
The used pharmaceutical carrier of prior art PVP-I is polyvinyl pyrrolidone (PVP), but PVP can only chelated iodine and increase the water solublity of iodine, and pathogenic bacterium on the wound surface are not but had any effect.And the new support 4-nonyl-2 that the present invention adopts, 6-dihydroxy-phenyl polyoxyethylene ether or 4-octyl group-2,6-dihydroxy-phenyl polyoxyethylene ether (being PON), this type of material except can chelated iodine and increase iodine the water solublity effect and, itself also has stronger bacteriostatic activity, therefore, the PON complex is higher than PVP-T(such as table 1 to the anti-infection ability of burn wound).And PVP needs dependence on import, cost an arm and a leg, and PON is homemade, and is cheap and easy to get, can reduce cost a joint foreign exchange.
(2) adopt the existing PVP-I of new substrate to use oil-soluble substrate, PON-I then adopts water-soluble base, the characteristics of the new substrate of this kind are to be easy to be coated with exhibition, burn wound's no greasy feeling in back, be easy to flushing, help keeping the wound surface cleaning, especially improved the wound surface breathability and the bad situation of water penetration that are caused because of oil-soluble substrate, guarantee the smooth and easy drain of wound surface, can correspondingly improve the healing rate of burn wound.
Two, second of PON-T of the present invention and prior art distinctive points is: contain the preparation technology of iodo-complexes, many usually use solvent methods or hybrid heating are finished, and the present invention then adopts easy aqueous solution and auxiliary agent reaction method, at room temperature reacts promptly.
Three, PON-I preparation of the present invention confirms by following result of the test the infection effect of burn wound.
Be that PON-I and the paired observation of PVP-I laboratory bactericidal effect are respectively the very strong Bacillus anthracoides brood cell of resistance to be acted on 30 minutes result with these two kinds of preparations, the sterilizing rate of PON-I is 99.84%, PVP-I is 98.50%, after effect 60 minutes, PON-I and PVP-I are respectively 99.99% and 99.02%, and the brood cell's ability of killing that shows the former is greater than latter's (as table 1).
Four, PON-T is by the experimental therapeutic outcome of II degree animal model of burn is estimated to the infection effect of burn wound.
(1) PON-I is P＜0.05 for the comparing result that the II degree animal model of burn that is subjected to the drug resistance infection of staphylococcus aureus carries out the anti-infective therapy front and back.
(2) establish PON-I treatment group and chloromycetin matched group the curative effect contrast observing result of anti-infective therapy of animal model of burn is Δ P＜0.01, show that the antibacterial effect of PON-I obviously is better than chloromycetin (as table 2).
Five, PON-T is to the clinical evaluation of II degree and III degree burn patient infection curative effect.
(1) to the observation of curative effect of II degree burn patient
If PON-I treatment group, select II degree burn patient 41 examples, other establishes SD-Ag(silver sulfadiazine commonly used) parallel control treatment group patient 21 examples, under the same conditions, respectively executing of two groups of patient burn woundes controlled with two medicines, the paired observation result, wound surface sampling positive bacterial culture number is 35 examples (positive rate accounts for 85.2%) before the medication of PON-I group, number positive is reduced to 7 examples (positive rate 17.1%) after the medication, negative conversion rate 80%, and wound surface sampling cultivation results before the medication of SD_Ag treatment group, number positive is 17 examples (positive rates 81%), number positive is reduced to 6 examples (28.6%) after the medication, and negative conversion rate is 64.3%(such as table 3).
(2) III degree burn patient anti-infective therapy
PON-I group and SD-Ag matched group, respectively select close III degree burn patient 10 examples of the state of an illness, 6 examples (60%) of antibacterial culturing number before medication are reduced to 2 examples (20%) after the PON-I group medication as a result, still are 7 examples (positive rate 70%) (as table 4) and compare no change before the number positive after the medication of SD-Ag group and the medication.The curative effect that this shows two medicines has significant difference.Be the curative effect of PON-I to the infection effect of II degree and III degree burn apparently higher than SD-Ag and PVP-T.
Through the burn wound of PON-T treatment, crust is complete, comes off naturally for up to 46 days, for plenty of time is won in the planned skin-grafting of burning of II degree III degree, for the cure rate of raising burn patient provides advantage.
As follows in conjunction with the embodiment that technique scheme provides.
Embodiment 1: the required raw-material prescription of preparation PON-T:
(1) carrier is selected 4-nonyl-2 for use, 6-dihydroxy-phenyl-polyoxyethylene ether or 4-octyl group-2,6-dihydroxy-phenyl-polyoxyethylene ether (PON).Its content requirement reaches 99.5%, absorptance 23-27, loss on drying≤0.5%, index of refraction 1,4870-1,4900, cloud point 65-70 ℃, pH4.5-6.5, ignition residue≤0.1%.
(2) substrate
1. medical sodium alginate, viscosity (20 ℃ of 1% aqueous solutions) 〉=0.02 Pa.S(204), loss on drying is not more than 22%, ignition residue (sulfate) 30-35%, and heavy metal (pb) arsenic (As) ferrum (Fe) meets the requirements, and colloid, starch meet examination requirements.
2. glycerol is medical
3. moisture medical distilled water
(3) auxiliary agent: potassium iodide, medical
Embodiment 2: contain the preparation of iodo-complexes
1. iodine tablet and auxiliary agent are placed glass or enamel or rigid plastics beaker, add small amount of moisture, stir,, make iodine solution the iodine tablet dissolving.
2. add 12 times of carrying agent viscous solution to iodine tablet place the glass garden at the bottom of flask or enamel reaction cylinder, the iodine solution with above-mentioned preparation slowly adds wherein again, the course of reaction that stirred under room temperature 2-3 hour promptly gets and contains iodo-complexes (PON-T).
Embodiment 3: the preparation of substrate
Earlier sodium alginate and glycerol are stirred, be mixed into pasty state, add a certain amount of moisture then and stir, put room temperature following a few hours, till the stiff gel of one-tenth.
This substrate can with sulfathiazole, ichthyol, phenol, thimerosal, Benzene Chloride, first azanol, boric acid, phenylmercuric nitrate, cresol compatibility.
After gel was made in this substrate itself or dosing, its chemical property was stable.
Subordinate list:
Table 1. PON-I and PVP-I are to Bacillus anthracoides brood cell killing effect relatively
| The average kill ratio (%) of different action times | |||
| Drug level (ppm) 30 minutes 60 minutes | |||
| PON-I 400 99.84 99.99 PVP-I 400 98.50 99.02 |
Annotate: 1. matched group on average reclaims the bacterium number: 1 * 10
6(cfu/ml)
2. operative temperature is 20 ℃, and 2% peptone is a protective agent.
Table 2. PON-I and chloromycetin are to the drug-resistant staphylococcus aureus curative effect relatively
| Amount of bacteria (individual/gram) wound surface area (cm 2） | ||||
| Drug therapy is treated the first seven day after the first seven day after | ||||
| PON-I 1.7×10 7±18.18 7.38×10 4± 148.56 4.95 ± 1.35 2.16 ± 0.63 chloromycetin 8.9 * 10 7±6.53 4.38×10 6±11.75 4.52±1.88 3.87±1.36 |
Annotate: the preceding ratio of P＜0.05(and treatment) Δ P＜0.01(and chloromycetin ratio)
Table 3. PON-I and SD-Ag are to burn wound's curative effect relatively
| Cultivate healing after cultivating medication before the medication | |||||||
| Medicine example number negative conversion rate (%) time | |||||||
| Number positive positive rate (%) number positive positive rate (%) (my god) | |||||||
| PON-I 41 35 85.2 7 17.1 80.0 11.8 SD-Ag 21 17 81.0 8 28.6 64.3 14.2 |
Annotate: be II degree burn patient, became crust in 4-6 days.
Table 4. PON-I and SD-Ag are to III degree burn curative effect relatively
| Skin graft survives after the preceding medication of medication | |||||||
| Medicine example number | |||||||
| Number positive positive rate (%) number positive positive rate (%) 90% above 80-75% | |||||||
| PON-I 10 6 60 2 20 10 0 SD-Ag 10 7 70 7 70 7 3 |
Annotate: crust is complete, and natural solution-off did not come off yet for up to 46 days and won the time for the planned skin-grafting of burning of III degree
Claims (4)
1, a kind of antimicrobial drug PON-I of burn wound (newly containing Surgidine ointment) and preparation method thereof hereinafter to be referred as PON-I, by the reactant+carrier of iodine and auxiliary agent form contain iodo-complexes and substrate is formed.
2, a kind of antimicrobial drug PON-T of burn wound as claimed in claim 1 and preparation method thereof, the substrate that it is characterized in that PON-T is to adopt water-soluble base.
3, a kind of antimicrobial drug PON-T of burn wound as claimed in claim 1 and preparation method thereof is characterized in that the iodo-complexes that contains of PON-I is to utilize moisture adding assistant stirring reaction and getting at room temperature.
4, a kind of antimicrobial drug PON-I of burn wound as claimed in claim 1 and preparation method thereof is characterized in that adopting 4-nonyl-2,6-dihydroxy-phenyl polyoxyethylene ether or 4-octyl group-2, and 6-dihydroxy-phenyl polyoxyethylene ether is as the carrier components of iodine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 91103111 CN1066979A (en) | 1991-05-20 | 1991-05-20 | The preparation method of antibiotics for burn wound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 91103111 CN1066979A (en) | 1991-05-20 | 1991-05-20 | The preparation method of antibiotics for burn wound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1066979A true CN1066979A (en) | 1992-12-16 |
Family
ID=4905899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 91103111 Pending CN1066979A (en) | 1991-05-20 | 1991-05-20 | The preparation method of antibiotics for burn wound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1066979A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103442728A (en) * | 2010-12-30 | 2013-12-11 | "抗感染类药物的科学中心"哈萨克斯坦工业及新技术部 | Antibacterial agent for treating infectious diseases of bacterial origin |
-
1991
- 1991-05-20 CN CN 91103111 patent/CN1066979A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103442728A (en) * | 2010-12-30 | 2013-12-11 | "抗感染类药物的科学中心"哈萨克斯坦工业及新技术部 | Antibacterial agent for treating infectious diseases of bacterial origin |
| CN103442728B (en) * | 2010-12-30 | 2017-04-12 | 抗感染类药物的科学中心 | Antibacterial agent for treating infectious diseases of bacterial origin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11116865B2 (en) | Antimicrobial silver iodate | |
| Hume et al. | The control of Staphylococcus epidermidis biofilm formation and in vivo infection rates by covalently bound furanones | |
| EP1216065B1 (en) | Silver-containing compositions, devices and methods for making | |
| US7576255B2 (en) | Silver-containing compositions, devices, and methods for making | |
| CN100471528C (en) | Liquid wound-dressing with functions of promoting heal of wound and bacterial-resisting | |
| US10709819B2 (en) | Method for coating catheters with a layer of antimicrobial agent | |
| CN108135745A (en) | Composition is formed for effective novel fast deposition film for the treatment of of wounds | |
| CN1089587C (en) | Stable cross-linked compound of polyvinyl pyrrolidone and iodine and method for preparation of said compound | |
| CN101411898B (en) | Organic/inorganic composite antibiotic catheters and preparation method thereof | |
| US9723843B2 (en) | Family of silver (I) periodate compounds having broad microbial properties | |
| RU2636530C2 (en) | Pharmaceutical compositions for treatment of wounds and burns | |
| CN110198731B (en) | Antimicrobial composition comprising sodium dimercaptopropane sulfonate and dimethyl sulfoxide, use of the composition, and wound treatment methods using the same | |
| US8568711B2 (en) | Antimicrobial compositions | |
| CN1066979A (en) | The preparation method of antibiotics for burn wound | |
| CN114456239A (en) | Shengtai element, external antibacterial peptide gel preparation prepared from Shengtai element and application of gel preparation | |
| CN1583165A (en) | Gel gent of Chiense forest frog bactericidal peptide | |
| van Hasselt et al. | Randomized controlled trial on the treatment of otitis externa with one per cent silver nitrate gel | |
| CN1583166A (en) | Chinese forest frog bactericidal peptide spray agent and its preparation | |
| CN111529682A (en) | Chemotaxis antibacterial nano material and preparation method and application thereof | |
| US11766505B2 (en) | Antimicrobial silver iodate | |
| CN108938559B (en) | DNA gel sterilization material, preparation method thereof and application of DNA gel sterilization material as sterilization material | |
| CN111213674B (en) | Compound with antibacterial activity and preparation method and application thereof | |
| RU2814059C1 (en) | Method of producing biocomposite materials with regenerative and antiseptic properties based on bacterial cellulose hydrogels | |
| RU2810573C2 (en) | Bioactive hydrogel based on high molecular weight chitosan and method of its extemporaneous production | |
| RU2812224C1 (en) | Anti-microbial application product with controlled release for treatment of inflammatory periodontal diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |